PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novartis, Biogen walk on Sangamo partnerships

Novartis and Biogen both walked away from separate neurodegenerative deals with Sangamo Therapeutics, leaving the California-based genomic medicine company scrambling to assess its options.

Novartis was the first to go. Early last week, the Novartis Institutes for BioMedical Research notified Sangamo that, effective June 11, 2023, it was terminating a deal inked back in July 2020. Novartis indicated to Sangamo that the termination relates to a recent strategic review. 

The deal had focused on leveraging Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors, against three neurodevelopmental targets, including autism spectrum disorder and other neurodevelopmental disorders. Novartis paid Sangamo a $75 million upfront license fee and Sangamo was eligible to earn from Novartis up to $720 million in milestone payments.

Before Sangamo could regroup from the bad news, Biogen added some more, notifying the company on Friday that effective June 15, 2023, it would be terminating its February 2020 agreement. Like Novartis, Biogen also told Sangamo the termination relates to a recent strategic review. 

The Biogen deal involved an upfront payment of $350 million with Sangamo eligible to receive up to $2.37 billion in potential milestones related to the development of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases.

Now, Sangamo says it will investigate alternative options to advance the neurological disease programs that were subject to both deals, including potential development internally or with a collaboration partner.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026